WO2009091121A2 - Composition comprising the extracts of lysimachia clethroides for prevention and treatment of cardiovascular diseases - Google Patents
Composition comprising the extracts of lysimachia clethroides for prevention and treatment of cardiovascular diseases Download PDFInfo
- Publication number
- WO2009091121A2 WO2009091121A2 PCT/KR2008/007485 KR2008007485W WO2009091121A2 WO 2009091121 A2 WO2009091121 A2 WO 2009091121A2 KR 2008007485 W KR2008007485 W KR 2008007485W WO 2009091121 A2 WO2009091121 A2 WO 2009091121A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- prevention
- lysimachia clethroides
- treatment
- composition
- Prior art date
Links
- 244000261422 Lysimachia clethroides Species 0.000 title claims abstract description 97
- 235000009773 Lysimachia clethroides Nutrition 0.000 title claims abstract description 97
- 239000000284 extract Substances 0.000 title claims abstract description 95
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 230000002265 prevention Effects 0.000 title claims abstract description 23
- 102000004722 NADPH Oxidases Human genes 0.000 claims abstract description 20
- 108010002998 NADPH Oxidases Proteins 0.000 claims abstract description 20
- 230000002792 vascular Effects 0.000 claims abstract description 19
- 230000036541 health Effects 0.000 claims abstract description 15
- 230000002883 vasorelaxation effect Effects 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 235000013376 functional food Nutrition 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 29
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 23
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 239000000287 crude extract Substances 0.000 claims description 21
- 241000196324 Embryophyta Species 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 5
- 208000029078 coronary artery disease Diseases 0.000 claims description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- 208000031225 myocardial ischemia Diseases 0.000 claims description 4
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 3
- 206010003119 arrhythmia Diseases 0.000 claims description 3
- 230000006793 arrhythmia Effects 0.000 claims description 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 208000001953 Hypotension Diseases 0.000 claims description 2
- 230000036543 hypotension Effects 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 206010048554 Endothelial dysfunction Diseases 0.000 abstract description 7
- 230000008694 endothelial dysfunction Effects 0.000 abstract description 7
- 230000008602 contraction Effects 0.000 abstract description 5
- 230000003389 potentiating effect Effects 0.000 abstract description 3
- 230000029865 regulation of blood pressure Effects 0.000 abstract description 3
- 230000033904 relaxation of vascular smooth muscle Effects 0.000 abstract description 2
- 208000019553 vascular disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 47
- 238000002360 preparation method Methods 0.000 description 28
- 238000012360 testing method Methods 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 14
- 210000000709 aorta Anatomy 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 12
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 12
- 238000005259 measurement Methods 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 210000004204 blood vessel Anatomy 0.000 description 11
- 210000004351 coronary vessel Anatomy 0.000 description 9
- 230000036542 oxidative stress Effects 0.000 description 9
- 101800000733 Angiotensin-2 Proteins 0.000 description 8
- 102400000345 Angiotensin-2 Human genes 0.000 description 8
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 8
- 235000013361 beverage Nutrition 0.000 description 8
- -1 isoquerdtrin Chemical compound 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000007758 minimum essential medium Substances 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 210000003556 vascular endothelial cell Anatomy 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 239000002034 butanolic fraction Substances 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- RYVMUASDIZQXAA-UHFFFAOYSA-N pyranoside Natural products O1C2(OCC(C)C(OC3C(C(O)C(O)C(CO)O3)O)C2)C(C)C(C2(CCC3C4(C)CC5O)C)C1CC2C3CC=C4CC5OC(C(C1O)O)OC(CO)C1OC(C1OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OCC(O)C(O)C1O RYVMUASDIZQXAA-UHFFFAOYSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000002040 relaxant effect Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- MQVRGDZCYDEQML-UHFFFAOYSA-N Astragalin Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 MQVRGDZCYDEQML-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000037093 Menstruation Disturbances Diseases 0.000 description 2
- 206010027339 Menstruation irregular Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 210000002403 aortic endothelial cell Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000002021 butanolic extract Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000002038 ethyl acetate fraction Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 239000002044 hexane fraction Substances 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- JPUKWEQWGBDDQB-QSOFNFLRSA-N kaempferol 3-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=CC(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O JPUKWEQWGBDDQB-QSOFNFLRSA-N 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
- 229960001802 phenylephrine Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 230000001196 vasorelaxation Effects 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-3',4',5,7-Tetrahydroxy-2,3-trans-flavan-3-ol Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- 229930013783 (-)-epicatechin Natural products 0.000 description 1
- 235000007355 (-)-epicatechin Nutrition 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- YNVZDODIHZTHOZ-UHFFFAOYSA-K 2-hydroxypropanoate;iron(3+) Chemical compound [Fe+3].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O YNVZDODIHZTHOZ-UHFFFAOYSA-K 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- RTATXGUCZHCSNG-TYSPDFDMSA-N Kaempferol-3-O-rutinoside Natural products OC1[C@H](O)[C@@H](O)C(C)O[C@H]1OCC1[C@@H](O)[C@@H](O)C(O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 RTATXGUCZHCSNG-TYSPDFDMSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- RTATXGUCZHCSNG-QHWHWDPRSA-N Nicotiflorin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 RTATXGUCZHCSNG-QHWHWDPRSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- YPWHZCPMOQGCDQ-UHFFFAOYSA-N Populnin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=CC(O)=CC=3)OC2=C1 YPWHZCPMOQGCDQ-UHFFFAOYSA-N 0.000 description 1
- 241000208476 Primulaceae Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 210000003433 aortic smooth muscle cell Anatomy 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- IFVTZJHWGZSXFD-UHFFFAOYSA-N biphenylene Chemical group C1=CC=C2C3=CC=CC=C3C2=C1 IFVTZJHWGZSXFD-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- JDEHKSHYQXNASH-UHFFFAOYSA-N kaempferol-3-O-beta-D-glucopyranoside Natural products OCC1OC(COC2=C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)cc4)C(O)C(O)C1O JDEHKSHYQXNASH-UHFFFAOYSA-N 0.000 description 1
- ZZZILDYSXRHUNY-UHFFFAOYSA-N kaempferol-3-O-glucoside Natural products OC1OC(COC2=C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)cc4)C(O)C(O)C1O ZZZILDYSXRHUNY-UHFFFAOYSA-N 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- RTATXGUCZHCSNG-ZFDPGQBLSA-N nicotiflorin Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2=C(c3ccc(O)cc3)Oc3c(c(O)cc(O)c3)C2=O)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 RTATXGUCZHCSNG-ZFDPGQBLSA-N 0.000 description 1
- RTATXGUCZHCSNG-UHFFFAOYSA-N nicotiflorine Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 RTATXGUCZHCSNG-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229960002460 nitroprusside Drugs 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004069 plant analysis Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003595 thromboxanes Chemical class 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
- A47K—SANITARY EQUIPMENT NOT OTHERWISE PROVIDED FOR; TOILET ACCESSORIES
- A47K1/00—Wash-stands; Appurtenances therefor
- A47K1/08—Accessories for toilet tables, e.g. glass plates, supports therefor
- A47K1/09—Holders for drinking glasses, tooth brushes, hair brushes, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A46—BRUSHWARE
- A46B—BRUSHES
- A46B17/00—Accessories for brushes
- A46B17/06—Devices for cleaning brushes after use
- A46B17/065—Sterilising brushes; products integral with the brush for sterilising, e.g. tablets, rinse, disinfectant
-
- A—HUMAN NECESSITIES
- A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
- A47K—SANITARY EQUIPMENT NOT OTHERWISE PROVIDED FOR; TOILET ACCESSORIES
- A47K5/00—Holders or dispensers for soap, toothpaste, or the like
- A47K5/18—Holders or dispensers for soap, toothpaste, or the like for both soap and toothpaste or the like; in combination with holders for drinking glasses, toothbrushes, or the like ; Toothpaste dispensers; Dental care centers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
- A61L2/08—Radiation
- A61L2/10—Ultraviolet radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Definitions
- NAD(P)H oxidase activity and vasorelaxant effect with a number of plant extracts, and finally confirmed the effects of potent inhibition of the activity of NAD(P)H oxidases, reduction of vascular oxidative stress, direct enhancement of the activity of endothelial-type nitric oxide synthase, relaxation of blood vessels and regulation of blood pressure, thus completing the present invention.
- preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories.
- non-aqueous solvents or suspending agents propylene glycol, polyethylene glycol, plant oils such as olive oil, injectable esters such as ethyl oleate, and the like can be used.
- base of the suppositories witepsol, Macrogol, Tween, cacao butter, laurin fat, glycerogelatin and the like can be used.
- the health functional beverage composition of the present invention is not particularly limited in containing other components, in addition to containing the extract as an essential component at the indicated proportions, and can contain additional components such as various flavoring agents or natural carbohydrates, as conventional beverages do.
- natural carbohydrates include conventional saccharides, such as monosaccharides, for example, glucose, fructose and the like; disaccharides, for example, maltose, sirrose and the like; and polysaccharides, for example, dextrin, cyclodextrin and the like, and sugar alcohols such as xylytol, sorbitol and erythritol.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Dentistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to a composition for treatment and prevention of cardiovascular diseases, containing an extract of Lysimachia clethroides. More particularly, the extract of Lysimachia clethroides strongly inhibits NAD(P)H oxidases, which are the main cause of vascular diseases, and at the same time, regulates contraction and relaxation of vascular smooth muscles to manifest a potent vasorelaxant effect, thereby improving the blood pressure regulation and vascular endothelial dysfunction. Therefore, a composition containing this as an active ingredient can be usefully utilized as a pharmaceutical prodvct or health functional food prodvct for the prevention and treatment of cardiovascular diseases.
Description
Description
COMPOSITION COMPRISING THE EXTRACTS OF LYSIMACHIA CLETHROIDES FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES
Technical Field
[1] The present invention relates to a composition for prevention and treatment of cardiovascular diseases, which comprises an extract of Lysimachia clethroides, and health functional food products. More particularly, the invention is characterized by containing, as an active ingredient, an extract of Lysimachia clethroides which has an effect of treating and preventing cardiovascular diseases by directly inhibiting NAD(P)H oxidases to inhibit oxidative stress, and at the same time, activating en- dothelial-type nitric oxide synthase to thereby regulate the contraction and relaxation of vascular smooth muscle cells. Background Art
[2] According to the statistics of the World Health Organization (WHO), it is reported that the world death rate for cardiovascular diseases in 1999 was 30% or greater, and the cardiovascular diseases will be the first ranking diseases causing death in developed countries in year 2010, while the increase rate of the diseases is high particularly in Asian countries including Japan, South Korea and the like. This is speculated to be attributable to an increase in the risk factors for coronary artery diseases, as a result of the coming aged society, changes in the dietary habits, and the like.
[3] Endothelial dysfunction is the main mechanism which indvces an extensive range of cardiovascular diseases, including hypertension, arteriosclerosis, hyperlipidemia, diabetes mellitus, obesity and the like (B runner H. et al., J. Hypertens., 2005, 23:233-246), since the discovery of abnormal relaxation of blood vessels in hypertensive patients in 1990 (Panza JA et al., New England Journal of Mededne, 323:22-27 ', 1990). Endothelial cells are epithelial cells lining along the cavities of blood vessels and lymph vessels, and their main function is to prodvce vasodilators and vasodilator mediators to regulate the vascular tone as well as the structure.
[4] A cardiovascular disease is a disease starting in the form of initial endothelial dysfunction and finally resulting in abnormality in the heart and vascular system. The name is a generic term for a group of abnormalities in the heart and blood vessels,
including, but not limited to, arteriosclerosis, hypertension, hyperlipidemia, coronary artery diseases (heart attack), cerebrovascular diseases (stroke, dementia), peripheral vascular diseases, arrhythmia, cardiac failure, congestive heart diseases, myocardial diseases, and the like.
[5] As for principal factors for the manifestation of cardiovascular diseases, there are known a variety of factors sirh as genetic factors, lifestyle, and complications of diabetes mellitus. From the standpoint of modern medicine, increases in the reactive oxygen species (ROS) and vascular oxidative stress as a result of an increase in the activity of NADPH oxidases, and a decrease in nitric oxide due to a decrease in the activity of endothelial-type nitric oxide synthase (eNOS), are known as principal factors. Nitric oxide which is produced by endothelia-type nitric oxide synthase, is a potent vasorelaxant factor, and also plays a critical role in the overall homeostatic regulation of the cardiovascular system by inhibiting platelet aggregation, proliferation of vascular muscle cells, vascular adhesion of monocytes, and expression of arteriosclerosis-associated proteins (Ibrstermann et al., Circulation, 113:1708-1714, 2005). However, an increase, caused by a number of factors, in the activity of NADPH oxidases which are in charge of the generation of active oxygen species in the blood vessels, leads to a decrease in the production of nitric oxide [Gryglewski et al., Nature, 320:454-456, 1986; Paravidni et al., Circulation Research, 91:54-61, 2002; Dusting et al., Clinical and Experimental Pharmacology and Physiology, 25:S34-41, 1998], and the active oxygen species thus produced bring about regulation of the expression of adhesive molecules [Lo et al., Am. J. Physiol., 264:L405-412, 1993], stimulation of the proliferation and migration of vascular smooth muscle cells (VSMC) [Griendling and Ushio-Fukai, J. Lab. Clin. Med., 132:9-15, 1998], regulation of lipoproteins having oxidizing power, and the like, to thereby cause cardiovascular diseases [Lynch and Frei, J. Lipid Res., 34:1745-1753, 1993]. Furthermore, the increased generation of active oxygen species in the blood vessels due to NAD(P)H oxidases, is associated with the impaired function of endothelial nitric oxide (NO) in patients having clinical risk factors for atherosclerosis and coronary artery diseases. Fundamentally, the generation of active oxygen species brings about contraction of blood vessels [Guzik et al., Cir. Res., 86:E85-90, 2000].
[6] In general, reduction of active oxygen species, suppression of downstream generation of active oxygen species, and induction of the activity of endothelial-type nitric oxide synthase, all through direct inhibition of NAD(P)H oxidases, are recognized as very important targets in the prevention and treatment of cardiovascular
diseases [Ibrstermann et al., Circulation, 113:1708-1714, 2005; Boggrell SA et al., Drug News Perspect, 17(9) 615-632, 2005; Inogirhi T., Curr. Drug Targets, 6(4):495-501, 2005; Muzaffar S. et al., Trends Cardiovasc Med., 15(8):278-282].
[7] To date, known as the substances inhibiting NAD(P)H oxidases are diphenylene ionodium (DPI) and 4-hydroxy-3-methoxyacetopoenone (Apocyin) [Holland J., et al., US 609051]. However, these substances have not been put into commercialization or clinical use because of the problems of toxicity and specificity. Furthermore, as nitric oxide regulators, there are available nitroprusside and nitroglycerine. However, these substances are also put into use only in the cases of emergency sirh as heart attack, because of the problems of resistance and toxicity in clinical uses.
[8] Meanwhile, Lysimachia clethroides is a perennial plant of family Primulaceae and is a herbaceous perennial commonly growing in the sun. It grows to a height of 50 to 100 cm, and grows in the wild state over the whole land of Korea as well as in Japan, Manchuria and China. It is also known as gooseneck loosestrife, and is known to treat irregular menstruation and leucorrhea in women, infant weight loss, hydrops, dysentery, bruises, pain in the posterior ear, and the like. In private practices, the plant has been long used in the treatment of irregular menstruation, dysentery and bruises. Since the plant has strong sour taste, it is also used in sour-tasting foods when used in cooking [Illustrated Book of Korean Plants, by Chang-Bok Lee, 1980; Illustrated Book of Korean Folk Medicines, by Jong-Hee Park, 2005; Encyclopedia of Local Medicines; Illustrated Book of Korean Medicinal Plants, by Chang-Su Yook, 1989, Natural Herbs, Healthy Herbs, Young-Han Kwon, 2005].
[9] In regard to researches on the components of Lysimachia clethroides, there have been reported astragalin, isoquerdtrin, kaempferol-3-O-rutinoside, kaempferol- 3-O-(2,6-di-O-rhamnopyranosylglu»pyranoside), kaempferol- 3-O-(rhamnopyranosylglucopyranoside),
(3-O-methyl-quercetin-7-O-[alpha-L-rhamnopyranosyl(l-2)-beta-D-glux)pyranoside), (-)-epicatechin, quercetin-3-O-beta-D-glu»pyranoside, kaempferol- 3-O-beta-D-glucopyranoside, and kaempferol-
3-O-[alpha-L-rhamnopyranosyl(l-6)-beta-D-glux>pyranoside] (Yasukawa K., et al., Yakugaku Zasshi, 105, 939, 1986; Jin-Suk Kim, et al., Yakhak Hoeji, 4, 325-330, 1993). The pharmacological effects of the extracts and isolated components of Lysimachia clethroides have been reported to exhibit antibacterial activity against food poisoning-associated microorganisms, anticancer activity, antioxidant effects, and the like (Ji-Sook Han, et al., Korean Journal of Ibod Science and Technology, 33,
772-783, 2001; Ki-Hwan Bae, et al., Korean Journal of Pharmacognosy, 27, 173-177, 1996; Seung-Eun Lee, et al., J. Korean Sx. Appl. Biol. Chem., 47, 265-269, 20W).
[10] However, no disclosure or teaching is given in the above-mentioned literatures, on that an extract of Lysimachia clethroides has effects of suppression of vascular oxidative stress, direct relaxation of blood vessels, enhancement of endothelial-type nitric oxide synthase aάtivty, and regulation of blood pressure, through inhibition of NADPH oxidases. Seung-Eun Lee et al. (J. Korean Sx. Appl. Biol. Chem., 47, 265-269, 2001) reported that an extract of Lysimachia clethroides inhibits the activity of angiotensin-converting enzymes. However, this article disclosed that although the concentration of the crude extract was very high, reaching up to 4000 μg/ml, the extract exhibited only slight activity inhibition against angiotensin-converting enzymes. Furthermore, a conclusion was made such that an n-butanol fraction of Lysimachia clethroides did not exert any influence on the activity of the angiotensin- converting enzymes, but rather increase the activity (an increase by 34%). Disclosure of Invention Technical Problem
[11] The inventors of the present invention conducted an investigation on the inhibition of
NAD(P)H oxidase activity and vasorelaxant effect with a number of plant extracts, and finally confirmed the effects of potent inhibition of the activity of NAD(P)H oxidases, reduction of vascular oxidative stress, direct enhancement of the activity of endothelial-type nitric oxide synthase, relaxation of blood vessels and regulation of blood pressure, thus completing the present invention.
[12] Particularly, in contrast to the report by Seung-Eun Lee et al., it was confirmed that a crude extract of Lysimachia clethroides has direct effects of vasorelaxation and the like at low concentrations of less than 10 μg/ml, regardless of angiotensin-converting enzymes. Furthermore, it was discovered that the aforementioned effects are enhanced with an n-butanol fraction.
[13] The present invention was designed based on such discoveries as described above, and an object of the invention is to provide a composition for prevention and treatment of a cardiovascular disease, comprising an extract of Lysimachia clethroides as an active ingredient.
[14] Another object of the present invention is to provide a health functional food product for prevention of a cardiovascular disease, comprising an extract of Lysimachia clethroides as an active ingredient.
Technical Solution
[15] To achieve the objects as described above, the composition for prevention and treatment of a cardiovascular disease of the present invention is characterized by containing an extract of Lysimachia clethroides as an active ingredient.
[16] The extract of Lysimachia clethroides is preferably extracted by using the leaves or the whole plant.
[17] The extract of Lysimachia clethroides is preferably extracted with a solvent selected from the group of water, a C -C lower alcohol, and a mixture thereof.
1 5
[18] Furthermore, the C -C lower alcohol is preferably methanol, ethanol or butanol.
[19] The extract of Lysimachia clethroides is preferably extracted with a 30 to 95 wt% aqueous solution of ethanol. [20] It is preferable that the extract of Lysimachia clethroides be extracted with a solvent selected from the group of water, a C -C lower alcohol and a mixture thereof, and the extract be re-extracted with butanol. [21] It is also preferable that the extract of Lysimachia clethroides be extracted with a solvent selected from the group consisting of water, a C -C lower alcohol and a mixture thereof, and concentrated to obtain a crude extract, and the crude extract be suspended in water, and re-extracted with hexane, ethyl acetate and butanol in this order.
[22] The crude extract of Lysimachia clethroides is preferably obtained at 30 to 950C.
[23] It is preferable that the crude extract and water be mixed and suspended at a volume ratio of 1:5 to 25 [24] It is also preferable that hexane, ethyl acetate or butanol and the suspension be mixed and extracted at a volume ratio of 1:0.1 to 2.0. [25] The butanol is preferably n-butanol.
[26] The extract of Lysimachia clethroides is characterized by having an NAD(P)H oxidase inhibitory activity. [27] The extract of Lysimachia clethroides is characterized by having a vasorelaxant effect. [28] The extract of Lysimachia clethroides is characterized by an effect of enhancing the activity of endothelial-type nitric oxide synthase. [29] The extract of Lysimachia clethroides is characterized by having effects of decreasing the blood pressure and reducing the vascular oxidative stress. [30] The cardiovascular disease may be selected from the group consisting of congestive heart diseases, coronary artery diseases (heart attack), ischemic heart diseases
(myocardial ischemia), hyperlipidemia, arteriosclerosis, hypertension, hypotension, arrhythmia, cardiac failure, vascular restenosis, cerebrovascular diseases (stroke, dementia), peripheral vascular diseases and metabolic diseases. [31] Meanwhile, the health functional food product for prevention of a cardiovascular disease of the present invention is characterized by containing an extract of Lysimachia clethroides as an active ingredient.
Advantageous Effects
[32] As discussed in the above, the extract of Lysimachia clethroides of the present invention strongly inhibits the activity of NAD(P)H oxidases and exhibits a vasorelaxant effect at the same time, and thus can be usefully utilized as a pharmaceutical composition or health functional food product for prevention and treatment of a cardiovascular disease. Brief Description of Drawings
[33] Hg. 1 is a diagram showing the measurement of the vasorelaxant activity of an extract of Lysimachia clethroides on swine coronary arteries.
[34] Hg. 2 is a diagram showing the measurement of the vasorelaxant activity of an extract of Lysimachia clethroides on the aorta of a white rat.
[35] Hg. 3 is a diagram showing the measurement of the degree of activity of endothelial- type nitric oxide synthase (eNOS) and Akt protein under the action of an extract of Lysimachia clethroides.
[36] Hg. 4 is a diagram showing the measurement of the degree of influence of an extract of Lysimachia clethroides on the heart rate.
[37] Hg. 5 is a diagram showing the measurement of the degree of decrease in vascular oxidative stress under the action of an extract of Lysimachia clethroides.
[38] Hg. 6 is a diagram showing the measurement of the degree of cytotoxicity of an extract of Lysimachia clethroides. Best Mode for Carrying out the Invention
[39] Hereinafter, preferred embodiments of the present invention will be described in detail. In the following description, numerous characteristic terms such as specific constituent elements are illustrated, but these are provided only for the purpose of providing an aid for more comprehensive understand of the present invention, and it will be obvious to those having ordinary skill in this technical field that the present invention can be carried out even without these characteristic terms. Furthermore, in the description of the present invention, if it is judged that specific explanation of any
related known function or constitution may unnecessarily make the gist of the invention unclear, the detailed explanation will be omitted.
[40] The extract of Lysimachia clethroides of the present invention can be obtained as follows.
[41] The whole plant, including roots and the aerial part, of Lysimachia clethroides can be used without limitation, in the form of plants collected from nature, cultivated plants, commercially available plants, or the like. The solvent for extraction is selected from the group consisting of water, a C -C lower alcohol, and a mixture thereof. The inventors of the present invention washed the twigs and leaves of Lysimachia clethroides to remove impurities and salts, and dried them. Subsequently, extraction was performed with a polar solvent such as water or a C -C lower alcohol such as methanol, ethanol or butanol, or a mixed solvent of these at a mixing ratio of about 1:0.1 to 1:10, preferably with a 30 to 95 wt% aqueous solution of ethanol, in a volume reaching about 5- to 50-fold, and preferably 10- to 30-fold, the weight of the Lys imachia clethroides sample, at 50 to 950C for 1 hour to 7 days. The above-described extraction process is repeated two or five times, and then the resultant is subjected to concentration under reduced pressure and/or freeze-drying, to obtain a crude extract of Lysimachia clethroides.
[42] Among the extracts of the present invention, a non-polar solvent- soluble extract can be obtained by suspending the aforementioned crude extract in distilled water, subsequently adding a non-polar solvent sirh as hexane, ethyl acetate or chloroform in a volume of about 0.1 to 100 times, and preferably about 1 to 5 times, the volume of the suspension, and performing extraction and isolation once to 10 times, and preferably two to five times. Furthermore, conventional fractionation processes can also be additionally carried out (Harborne, J.B., Phytochemical methods: A guide to modern techniques of plant analysis, 3r Ed., pp. 6-7, 1998).
[43] More preferably, the crude extract of Lysimachia clethroides obtained by the above- described processes, preferably an extract of Lysimachia clethroides in an aqueous solution of ethanol, is subjected to sequential solvent fractionation with organic solvents such as n-butanol, hexane and ethyl acetate, in order from less polar solvent to more polar solvent, preferably in order of hexane, ethyl acetate and n-butanol, and to concentration under reduced pressure, and thus hexane, ethyl acetate and n-butanol fractions of Lysimachia clethroides can be obtained.
[44] The present invention provides a composition for prevention and treatment of a cardiovascular disease, which comprises the crude extract or non-polar solvent-soluble
extract of Lysimachia clethroides obtained by the above-described production method, as an active ingredient.
[45] The composition for prevention and treatment of a cardiovascular disease according to the present invention contains 0.1 to 99% by weight of the aforementioned extract based on the total weight of the composition.
[46] The composition containing the extract of Lysimachia clethroides of the present invention may further contain appropriate carriers, excipients and diluents that are conventionally used in the production of compositions.
[47] The pharmaceutical dosage form of the extract of the present invention can be used in the form of pharmaceutically acceptable salts thereof, and also can be used alone, or in the form of conjugate as well as appropriate assembly with other pharmaceutically active compounds.
[48] The pharmaceutical composition containing the extract according to the present invention can be used after being formulated into oral formulations svch as powders, granules, tablets, capsules, suspensions, emulsions, syrups and aerosols, and into topical formulations, suppositories and sterile injectable solutions, respectively according to conventional methods.
[49] As for the carriers, excipients and diluents that can be contained in the composition containing the extract, there may be mentioned lactose, dextrose, svcrose, sorbitol, mannitol, xylytol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, non-crystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talς magnesium stearate, and mineral oil.
[50] In the case of formulating into preparations, they are prepared using conventionally used diluents or excipients, such as fillers, bulking agents, binding agents, wetting agents, disintegrants and surfactants.
[51] Examples of solid preparations for oral administration include tablets, pills, powders, granules, capsules and the like, and these solid preparations are prepared by mixing at least one exdpient, for example, starch, calcium carbonate, sucrose or lactose, gelatin and the like to the aforementioned extract. Furthermore, in addition to simple excipients, lubricants such as magnesium stearate and talc are also used.
[52] Examples of liquid preparations for oral administration include suspensions, liquids for internal use, emulsions, syrups and the like. These liquid preparations may include various exdpients, for example, wetting agents, sweeteners, fragrances, preservatives and the like, in addition to water and liquid paraffins, which are frequently used simple
diluents.
[53] Examples of preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. As non-aqueous solvents or suspending agents, propylene glycol, polyethylene glycol, plant oils such as olive oil, injectable esters such as ethyl oleate, and the like can be used. As the base of the suppositories, witepsol, Macrogol, Tween, cacao butter, laurin fat, glycerogelatin and the like can be used.
[54] A preferable amount of administration of the extract of the present invention may vary with the condition and weight of the patient, severity of the disease, form of drug, the route and period of administration, but can be appropriately selected by a person having ordinary skill in the art. However, for preferable effects, it is desirable to administer the extract of the present invention in an amount of 0.0001 to 100 mg/kg, and preferably 0.001 to 100 mg/kg, per day. Administration may be carried out once a day, or may be carried out several times a day. The amount of administration is not intended to limit the scope of the invention by any means.
[55] The present invention provides a health functional food product containing the aforementioned extract showing an effect of preventing a cardiovascular disease, and sito- logically acceptable food additives.
[56] As for the health functional food products which can be added with an extract of
Lysimachia clethroides, for example, there may be mentioned various general food products, beverages, chewing gums, tea, vitamin complexes, and the like.
[57] The extract of Lysimachia clethroides can also be added to foods or beverages for the purpose of obtaining an effect of preventing a cardiovascular disease. In this case, the amount of the extract in a food product or beverage may be 0.01 to 15% by weight based on the total weight of the food. The amount of the extract in a health beverage composition may be 0.02 to 5 g, and preferably 0.3 to 1 g, relative to 100 g of the total weight of the beverage.
[58] The health functional beverage composition of the present invention is not particularly limited in containing other components, in addition to containing the extract as an essential component at the indicated proportions, and can contain additional components such as various flavoring agents or natural carbohydrates, as conventional beverages do. Examples of the aforementioned natural carbohydrates include conventional saccharides, such as monosaccharides, for example, glucose, fructose and the like; disaccharides, for example, maltose, sirrose and the like; and polysaccharides, for example, dextrin, cyclodextrin and the like, and sugar alcohols such as xylytol,
sorbitol and erythritol. As the flavoring agents in addition to the aforementioned agents, thaumatin, stevia extracts, for example, levaudioside A, glycyrrhizin and the like; and synthetic flavoring agents, for example, saccharin, aspartame and the like can be advantageously used. The proportion of the natural carbohydrates is generally about 1 to 20 g, and preferably about 5 to 12 g, per 100 g of the composition of the present invention. [59] In addition to these, the extract of the present invention may contain various nutrients, vitamins, minerals (electrolytes), synthetic and natural flavoring agents, colorants and weighting agents (cheese, chooolate and the like), pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, antiseptics, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. In addition thereto, the extracts of the present invention may contain natural fruit juices, and fruit fleshes for the production of fruit juice beverages and vegetable beverages. These components can be used individually or in combinations. In this case, the proportion of the additives is not critical, but is generally selected from the range of 0.01 to about 20 parts by weight per 100 parts by weight of the extract of the present invention.
[60] Hereinafter, the present invention will be described more specifically, by making reference to the following Examples and Test Examples. Mode for the Invention
[61] Example 1 : Preparation of crude extract of Lysimachia clethroides
[62] Lysimachia clethroides collected in Kangwon-do Province was washed with water to remove impurities, and then were dried and crushed. In an extraction vessel, 25 g of Lysimachia clethroides, and 500 ml in total of a 70 wt% aqueous solution of ethanol were added, and thermal extraction was repeatedly performed three times at 7O0C, each time taking 3 hours, under reflux cooling. The resultant was filtered through a filter paper, and the filtrate was concentrated under reduced pressure in a water bath at 4O0C, and was freeze-dried. As a result, 53 g of a crude extract of Lysimachia clethroides was obtained.
[63] Example 2: Preparation of fractions of crude extract of Lysimachia clethroides
[64] 5 g of the crude extract of Lysimachia clethroides obtained in Example 1 were respectively suspended in 50 ml of purified water. The resultant was subjected to sequential solvent fractionation three times respectively, with 50 ml each of hexane, ethyl acetate and n-butanol in this order, to obtain the respective solvent fractions, and these were concentrated under reduced pressure. As a result, a hexane fraction, an
ethyl acetate fraction and an n-butanol fraction of Lysimachia clethroides were obtained.
[65] Test Example 1 : Measurement of inhibitory effect of extracts of Lysimachia clethroides on NAD(P)H oxidase activity
[66] The crude extract and fractions of Lysimachia clethroides prepared in Example 1 and
Example 2 as described above were subjected to the measurement of an effect of inhibiting the activity of NAD(P)H oxidases, which are index enzymes for the development of cardiovascular diseases. To this end, the arterial smooth muscle cells of white rat (Rat aortic smooth muscle cells; RASMC) and the vascular endothelial cells of calf (Bovine aortic endothelial cells; BAECs) were used to compare the changes in the NADPH oxidase activity, and the results are as shown in the following Table 1. Hrst, the arterial smooth muscle cells and the vascular endothelial cells were respectively mixed with MEM (minimum essential medium), DMEM (Dubleco's minimum essential medium) and a 10% FBS (fetal bovine serum) solution, and the cells were respectively incubated on a 96-well plate for 24 hours under the conditions of 5% CO /370C. Then, the cells were incubated again for 24 hours in the culture
2 solution with FBS excluded. After the cells were stabilized, the cells were washed with HBSS (Hank's balanced salt solution). These cells were shaken with the extract of Lysimachia clethroides obtained in the Example 1, and then the mixture was allowed to react for 15 minutes and washed again with HBSS. Subsequently, 100 mM NAD(P)H and 5 μM Ludgenin were added to the reaction liquid, and the activity of NAD(P)H oxidases was measured for one hour, using a luminescence reader (Victor Light, PerkineElmer). The test was operated three times, while repeated 2 to 7 times for each operation. Subsequently, the activity of the control group and the activity of the sample-treated group were compared, and the IC50 values were calculated. The IC50 value is the concentration, expressed in μg/ml, of a test material, at which 50% of the NADPH oxidase activity is inhibited. [67] Table 1
[Table 1]
[Table ]
Inhibitory effect of extracts of Lysimachia clethroides on NADPH oxidase activity
(unit: μg/ml)
[68] As shown in the Table 1, it can be seen that the extracts of Lysimachia clethroides of the present invention are excellent in the extent of inhibiting the activity of NADPH oxidases of the vascular cells. Furthermore, among the fractions, it can be seen that the n-butanol extract shows excellent effects.
[69] Test Example 2: Measurement of vasorelaxant effect of extracts of Lysimachia clethroides (coronary arteries and aorta)
[70] The vasorelaxant effects of the crude extract and fractions of Lysimachia clethroides prepared in the Example 1 and Example 2 were verified. To this end, a comparison was made on the effects of relaxing the coronary arteries of a pig heart and the rat aorta, and the results are as shown in Hg. 1, Table 2 (coronary arteries) and Table 3 (aorta). The coronary arteries were extracted from a pig heart purchased immediately after slaughter at the butchery. The aorta was extracted from a male SD (Sparague-Dawley) white rat, was immersed in the Krebs solution (pH 7.4) containing 18 mM NaCl, 47 mM KCl, LI mM MgSO , 1.2 mM KH PO , 1.5 mM CaCl , 25 mM
4 2 4 2
NaHCO , and 10 mM ghxose to remove the connective tissue and fats, and then was cut into a specimen of about 3 mm in length.
[71] The prepared coronary artery and aorta specimen were fixed in the Krebs solution at
370C, which had been saturated with 95% O and 5% CO gases. The isometric
2 2 tensions of the specimens were measured with a Grass physiograph (HugoSachs, Germany) equipped with a force-displacement transducer (HugoSachs, Germany). In the case of the coronary arteries, the arteries were first contracted to 80% of the maximum vascular contraction by using U46619 (1 to 60 nM), which is a thromboxane derivative. After 10 minutes therefrom, the arteries were relaxed with 300 nM
Bradykinin, the safety of the vascular endothelial cells was measured, and then the arteries were washed three times with the Krebs solution to perform the experiment. The measurement of changes in the vasorelaxant effect was carried out by first contracting the arteries with the drug U46619, and then the relaxation reaction induced by the extracts of Lysimachia clethroides was tested in a concentration-dependent manner.
[72] In the case of the aorta of white rat, the aorta was contracted to 80% of the maximum vascular contraction by using phenylephrine. After 15 minutes therefrom, the aorta was relaxed with 10 μM acetylcholine, the safety of the vascular endothelial cells was measured, and then the aorta was washed three times with the Krebs solution to perform the experiment. The measurement of changes in the vasorelaxant effect was carried out by first contracting the aorta with the drug phenylephrine, and then the relaxation reaction induced by the crude extract and fraction extracts of Lysimachia clethroides was tested in a concentration-dependent manner. This test was repeatedly carried out using the blood vessels extracted from 5 to 10 different individuals. The ED50 value refers to the concentration (μg/ml) of the sample at which the contracted blood vessels show 50% vasorelaxation as a result of the treatment with the sample.
[73] Table 2 [Table 2] [Table ]
Relaxant effect of extracts of Lysimachia clethroides on swine coronary arteries (unit: μg/ml)
[74] Table 3
[Table 3]
[Table ]
Relaxant effect of extracts of Lysimachia clethroides on white rat aorta (unit: μg/ml)
[75] As a result, as shown in Hg. 1, the extracts of Lysimachia clethroides of the present invention started significant relaxation from the concentration of 1 to 10 μg/ml, and reached 96+2% relaxation at the concentration of 30 μg/ml. As shown in Table 2 and Table 3, it can be seen that the extracts of Lysimachia clethroides are excellent in the extent of relaxing the blood vessels of the coronary arteries and the aorta. Among the fractions, it can be seen that the n-butanol extract shows excellent effects.
[76] Test Example 3: Test with extracts of Lysimachia clethroides on endothelial-type nitric oxide synthase activity
[77] Observations were made on the effects of the crude extract of Lysimachia clethroides prepared in the Example 1 and Example 2 on the enhancement of the activity of endothelial-type nitric oxide synthase. The above-mentioned effects were compared on the basis of the degree of phosphorylation of serine residue 1177 of the endothelial- type nitric oxide synthase (eNOS) and serine residue 473 of Akt of bovine aortic endothelial cells. The results are presented in Hg. 3.
[78] Hrst, the vascular endothelial cells were mixed with DMEM (Dubleco's minimum essential medium) and a 10% EBS (Fetal bovine serum) solution and incubated, and then the cells were incubated again for 24 hours in the culture solution with FBS excluded. After the cells were stabilized, the cells were treated with the samples at the respective concentrations, and then were allowed to react for 30 minutes. Then, the proteins were extracted and centrifuged, and the supernatant was collected to remove debris of the cells. The extracted proteins were subjected to electrophoresis on SDS- polyacrylamide gel, and then the proteins in the gel were blotted with a nitrocellulose membrane. After blocking with 3% BSA for one hour, the antibodies of phospho- eNOS and phospho-Akt (Cell Signaling, the USA) were incubated overnight at 40C at a ratio of 1:1,000. Subsequently, secondary antibodies diluted at a ratio of 1:2000 were
treated and incubated at ambient temperature for one hour, and then the secondary antibodies were developed by chemiluminescence.
[79] As a result, as shown in Hg. 3, it can be seen that the extracts of Lysimachia clethroides show high effects of enhancing the activation of endothelial-type nitric oxide synthase (phospho-eNOS), which produces nitric oxide, and a high degree of increase in the activation of Akt (phospho-Akt), which is an upper regulatory factor.
[80] Test Example 4: Test of effects of extracts of Lysimachia clethroides in animal model of cardiovascular disease
[81] The hypotensive effects in diseased animals, and the effects on the improvement of vascular oxidative stress and the improvement of endothelial dysfunction, exerted by the extracts of Lysimachia clethroides obtained in Example 2, were verified. To this end, a comparison was made on the extent of the effects in a disease model induced by angiotensin 2, and the results are presented in Hg. 4, Hg. 5, Eg. 6 and Table 4
[82] Male SD (Sparague-Dawley, 6 weeks old) white rats were purchased from Orientbio,
Inc., and the rats were acclimatized for one week while freely supplying solid feedstuff and water in a small animal breeding chamber which was regulated to have a light- dark period of 12 hours. Then, the rats were arbitrarily grouped into a control group and an angiotensin 2-treated group, with each group including 6 animals. From three days before the treatment with angiotensin 2, the extracts of Lysimachia clethroides obtained in Example 2 were respectively suspended in 0.5% CMC (carboxymethylcellulose) at a concentration of 100 mg/kg, and the suspensions were orally administered twice a day. The control group was administered with 0.5% CMC only. Angiotensin 2 was dissolved in physiological saline at a concentration of 65 ng/ min/kg, and the solution was placed in a mini-osmotic pump (Alzet Model 2002). The white rats were anesthetized, and the angiotensin 2 treatment was carried out by cutting the skin open, and inserting the mini-pump in the interscapular region. The blood pressure measurement was conducted simultaneously with the initiation of oral administration, and further measurements were made once in two days for 2 weeks, one hour after the oral administration in the morning. The specimen was heated in advance for about 10 minutes at 45 to 5O0C, and then the maximum blood pressure (systolic pressure) of the tail artery was measured in a non-invasive manner by the tail- cuff plethysmography method using an automated blood pressure recording system. The heart rate was also measured at the same time.
[83] The aorta was extracted in the same manner as in Test Example 2, and the degree of staining by DHE (dihydroetidium) and the degree of relaxation by acetylcholine were
characterized to measure the extents of vascular oxidative stress and vascular endothelial dysfunction. The results were compared with the results of the control group.
[84] Table 4 [Table 4] [Table ] Hypotensive effects of extracts of Lysimachia clethroides (unit: mmHg)
[85] As a result of the test, it can be seen from the Table 4 that the blood pressure increase in the test animals induced by angiotensin 2 was significantly inhibited by the administration of the extracts of Lysimachia clethroides.
[86] The increase in the heart rate was measured, and as a result, as shown in Hg. 4, it was confirmed that the extracts of Lysimachia clethroides do not have adverse side effects on the heart, sirh as tachycardia.
[87] Furthermore, as shown in Hg. 5, it can be seen that the increase in vascular oxidative stress induced by angiotensin 2 is strongly inhibited by the administration of the extracts of Lysimachia clethroides (Hg. 5 is a product of black-and-white modification of a photograph which indicates the object in red and the background in black, and at the time of modification, the background was rendered white for clear distinction of the object).
[88] The relaxation induced by 0.01 μM acetylcholine in the animals treated with angiotensin 2, was compared with that in the control group, and it was found that vascular endothelial dysfunction oxurred in which relaxation does not oxur smoothly (control group - 27%, acetylcholine group - 8%). It can be seen that sirh vascular endothelial dysfunction is improved by the administration of the extract of Lysimachia clethroides (31%).
[89] Test Example 5: Test on cytotoxicity of extracts of Lysimachia clethroides [90] A comparison was made for the crude extract of Lysimachia clethroides prepared in the Example 1 and Example 2 on the extent of cytotoxicity, and the results are as shown in Hg. 6
[91] Arterial smooth muscle cells were mixed with MEM (minimum essential medium) and a 10% FBS (fetal bovine serum) solution, and the cells were incubated for 24 hours under the conditions of 5% CO /370C. After the cells were stabilized, the cells
2 were treated with the extracts of Lysimachia clethroides obtained in the Example 2, shaken, and allowed to react for 24 hours. Thereafter, the cells were incubated for one hour in the presence of an MTS solution (CellTiter 96 Aqueous One Solution,
Promega), and then the absorbance at 490 nm was measured. [92] As shown in Hg. 6, it can be seen that the extracts of Lysimachia clethroides of the present invention were not found to have any influence on the survival of cells, and are very safe drugs.
[93] Test Example 6: Statistical processing
[94] The significance of the test results was determined by performing the Student t-test and one-way ANOVA test with the experimental results, such that there is a significant difference in the case where p is 0.05 or less. [95] Preparation examples of the pharmaceutical composition and health functional food products containing the extract of the present invention will be described in the following, but the present invention is intended not to limit them, but to specifically describe them.
[96] Preparation Example 1 : Production of powder preparation
[97] Powdered extract of Lysimachia clethroides 20 mg
[98] Lactose 100 mg
[99] Talc 10 mg
[100] The components were mixed and filled in a sealed pack, and thereby a powder preparation was produced.
[101] Preparation Example 2: Production of tablet preparation [102] Powdered extract of Lysimachia clethroides 10 mg [103] Corn starch 100 mg [IW] Lactose 100 mg [105] Magnesium stearate 2 mg [105] The components were mixed and then tableted aαcording to a conventional tablet production method, and thereby a tablet preparation was produced. [107] Preparation Example 3: Production of capsule preparation [108] Powdered extract of Lysimachia clethroides 10 mg [109] Crystalline cellulose 3 mg [110] Lactose 148 mg
[111] Magnesium stearate 2 mg
[112] According to a conventional capsule production method, the components were mixed and filled in gelatin capsules, and thereby a capsule preparation was produced.
[113] Preparation Example 4: Production of injectable preparation
[114] Powdered extract of Lysimachia clethroides 10 mg
[115] Mannitol 180 mg
[116] Sterile distilled water for injection 2794 mg
[117] Na HPO 12H O 26 mg
2 4 2
[118] According to a conventional production method for injectable preparation, an injectable preparation was produced at the aforementioned component contents per ampoule (2 ml).
[119] Preparation Example 5: Production of liquid preparation
[120] Powdered extract of Lysimachia clethroides 10 mg
[121] High-fructose corn syrup 1O g
[122] Mannitol 5 g
[123] Purified water Appropriate amount
[124] According to a conventional production method for liquid preparation, the components were added and dissolved in purified water, an appropriate amount of lemon flavor was added thereto, the components were mixed, and the total volume was adjusted to 100 ml by adding purified water. This was filled in a brown bottle and sterilized, and thereby a liquid preparation was produced.
[125] Preparation Example 6: Production of health drink
[126] Powdered extract of Lysimachia clethroides 10 mg
[127] Vitamin C 15 g
[128] Vitamin E (powdered) 100 g
[129] Iron lactate 19.75 g
[130] *135Zinc oxide 3.5 g
[131] Nicotinic add amide 3.5 g
[132] Vitamin A 0.2 g
[133] Vitamin Bl 0.25 g
[134] Vitamin B2 0.3 g
[135] Water Appropriate amount
[136] According to a conventional production method for health drink, the components were mixed, the mixture was heated under stirring at 850C for about one hour, and the resulting solution was filtered. The filtrate was placed in a sterilized 2-liter container,
sealed, sterilized, and refrigerated, and this was used in the production of the health drink compositions according to the present invention. In the above-given compositional ratios, components which are relatively suitable for favorite drinks were mixed and composed as a preferred Example, but the mixing ratio may be arbitrarily modified in accordance with the geographical and racial preference, sirh as of the class of consumers or consumer country, the uses, or the like.
Claims
[1] A composition for prevention and treatment of a cardiovascular disease, comprising an extract of Lysimachia clethroides as an active ingredient.
[2] The composition for prevention and treatment of a cardiovascular disease aαjording to claim 1, wherein the extract of Lysimachia clethroides is an extract of the leaves or the whole plant.
[3] The composition for prevention and treatment of a cardiovascular disease aαjording to claim 1, wherein the extract of Lysimachia clethroides is extracted with a solvent selected from the group consisting of water, a C -C lower alcohol, and a mixture thereof.
[4] The composition for prevention and treatment of a cardiovascular disease aαjording to claim 3, wherein the extract of Lysimachia clethroides is extracted with a 30 to 95 wt% aqueous solution of ethanol.
[5] The composition for prevention and treatment of a cardiovascular disease aαjording to claim 3, wherein the extract of Lysimachia clethroides is extracted with a solvent selected from the group consisting of water, a C -C lower alcohol
1 3 and a mixture thereof, and the resultant is re-extracted with butanol.
[6] The composition for prevention and treatment of a cardiovascular disease aαjording to claim 3, wherein the extract of Lysimachia clethroides is extracted with a solvent selected from the group consisting of water, a C -C lower alcohol
1 3 and a mixture thereof, and concentrated to obtain a crude extract, and the crude extract is suspended in water, and re-extracted with hexane, ethyl acetate and butanol in this order.
[7] The composition for prevention and treatment of a cardiovascular disease aαjording to claim 1, wherein the extract of Lysimachia clethroides has an NAD(P)H oxidase inhibitory activity.
[8] The composition for prevention and treatment of a cardiovascular disease aαjording to claim 1, wherein the extract of Lysimachia clethroides has a vasorelaxant effect.
[9] The composition for prevention and treatment of a cardiovascular disease aαjording to any one of claims 1 to 8, wherein the cardiovascular disease is selected from the group consisting of congestive heart diseases, coronary artery diseases (heart attack), ischemic heart diseases (myocardial ischemia), hyper- lipidemia, arteriosclerosis, hypertension, hypotension, arrhythmia, cardiac
failure, vascular restenosis, cerebrovascular diseases (stroke, dementia), peripheral vascular diseases and metabolic diseases.
[10] A health functional food prodirt for prevention of a cardiovascular disease, comprising an extract of Lysimachia clethroides as an active ingredient.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08870585A EP2240191A4 (en) | 2008-01-18 | 2008-12-17 | Composition comprising the extracts of lysimachia clethroides for prevention and treatment of cardiovascular diseases |
CN2008801250721A CN101969969A (en) | 2008-01-18 | 2008-12-17 | Composition comprising the extracts of lysimachia clethroides for prevention and treatment of cardiovascular diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080005782A KR100948332B1 (en) | 2008-01-18 | 2008-01-18 | Composition Comprising the Extracts of Lysimachia clethroides for Prevention and Treatment of Cardiovascular Diseases |
KR10-2008-0005782 | 2008-01-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009091121A2 true WO2009091121A2 (en) | 2009-07-23 |
WO2009091121A3 WO2009091121A3 (en) | 2009-09-03 |
Family
ID=40885751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2008/007485 WO2009091121A2 (en) | 2008-01-18 | 2008-12-17 | Composition comprising the extracts of lysimachia clethroides for prevention and treatment of cardiovascular diseases |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2240191A4 (en) |
KR (1) | KR100948332B1 (en) |
CN (1) | CN101969969A (en) |
WO (1) | WO2009091121A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100989093B1 (en) | 2008-01-18 | 2010-10-25 | 한화제약주식회사 | Composition Comprising the Extracts of Branch of Lindera obtusiloba for Prevention and Treatment of Cardiovascular Diseases |
KR101168566B1 (en) | 2010-05-20 | 2012-07-27 | 재단법인 제주테크노파크 | Compostion and Method for Controling Plant Disease Occurred by Magnaporthe grisea |
KR102014824B1 (en) | 2018-05-09 | 2019-08-28 | 주식회사 진생바이팜 | Health food composition for vascular relaxation and anti-thrombotic effects comprising Black Ginseng Radix, Salviae Miltiorrhizae Radix, Leonuri Herba and Cnidii Rhizoma |
CN110419742A (en) * | 2018-08-07 | 2019-11-08 | 湖南炎帝生物工程有限公司 | Nostoc composition and its application in adjusting blood lipid, prevention and/or treatment atherosclerosis |
WO2023128540A1 (en) * | 2021-12-31 | 2023-07-06 | 한국 한의학 연구원 | Composition for preventing, ameliorating, or treating metabolic diseases, containing extract of lysimachia mauritiana as active ingredient |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1173028C (en) * | 1999-04-01 | 2004-10-27 | 宋栋梁 | Chiense herbal medicine wine |
KR100535269B1 (en) * | 2003-08-27 | 2005-12-09 | 학교법인 한림대학교 | Composition comprising extract from lysimachiae herba for preventing and treating arteriosclerosis and enhancement of immunity |
CN1278737C (en) * | 2003-12-17 | 2006-10-11 | 昆明紫健生物技术有限公司 | Compound medicinal formulation with bioactivity |
CN100358530C (en) * | 2004-11-11 | 2008-01-02 | 云南白药集团股份有限公司 | Medicine prepn for treating cerebral apoplexy and its prepn |
CN101199563B (en) * | 2007-12-14 | 2010-06-02 | 苏州大学 | Use of Loosestrife total saponine in preparing medicine for treating liver cancer |
-
2008
- 2008-01-18 KR KR1020080005782A patent/KR100948332B1/en not_active IP Right Cessation
- 2008-12-17 WO PCT/KR2008/007485 patent/WO2009091121A2/en active Application Filing
- 2008-12-17 EP EP08870585A patent/EP2240191A4/en not_active Withdrawn
- 2008-12-17 CN CN2008801250721A patent/CN101969969A/en active Pending
Non-Patent Citations (1)
Title |
---|
See references of EP2240191A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP2240191A4 (en) | 2011-04-13 |
CN101969969A (en) | 2011-02-09 |
EP2240191A2 (en) | 2010-10-20 |
WO2009091121A3 (en) | 2009-09-03 |
KR20090079650A (en) | 2009-07-22 |
KR100948332B1 (en) | 2010-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8734866B2 (en) | Composition comprising the extracts of lindera obtusiloba for prevention and treatment of cardiovascular diseases | |
KR101158856B1 (en) | Compositions for the prevention and treatment of obesity, hyperlipidemia, atherosclerosis, fatty liver, diabetes mellitus or metabolic syndrome comprising extracts or fractions of Glycine max leaves as an active ingredient | |
KR100834348B1 (en) | Composition comprising the extracts of dictyota coriaceum for prevention and treatment of cardiovascular dyscrasia | |
EP2240191A2 (en) | Composition comprising the extracts of lysimachia clethroides for prevention and treatment of cardiovascular diseases | |
KR101427784B1 (en) | An anti-diabetes composition comprising Ginseng Radix and mulberry tree extract as effective ingredients | |
KR101692032B1 (en) | Anti-cancer composition containing erythronium japonicum extract | |
KR101987554B1 (en) | Method of the sprout barley mixture tea increased content of antioxidant or active ingredient of Anti-diabetic with eliminating the unpleasant odor of sprout barley, powder of silkworm and leaves of Cudrania tricuspidata | |
KR20150077794A (en) | Anti-obesity composition comprising herbal extracts as an active ingredient | |
KR100569089B1 (en) | Composition having brain function and congnition enhancing activity | |
KR101681980B1 (en) | Compositions for prevention or treatment of diabetic complications comprising extract of Colona auricaulata | |
KR20120115471A (en) | A composition comprising boiled powder or extract of glycine soja seed for the prevention and treatment of diabetes mellitus and diabetic complication | |
KR20130099476A (en) | Food composition for preventing or improving diabetes contaning extract of lespedeza maximowiczii | |
KR20060015055A (en) | Composition comprising the crude extract of the hydrangea serrata seringe var. thumbergii sugimoto for lowering blood glucose and hyperlipidemia | |
KR101596006B1 (en) | Composition for Prevention and Treatment of Cardiovascular Diseases | |
KR101001159B1 (en) | Composition for preventing or improving the diabete containing eriobotrya japonica extract | |
KR20150072659A (en) | Hepatoprotective composition containing smilax china extract | |
KR102025572B1 (en) | Composition for preventing, ameliorating or treating metabolic diseases comprising mixture of Diospyros lotus leaf and grape fruit stem extract as effective component | |
KR20130082249A (en) | Composition for preventing or improving the metabolic syndrome containing parthenocissus tricuspidata extract | |
KR20130082250A (en) | Composition for preventing or improving the hypertension containing parthenocissus tricuspidata extract | |
KR20100002239A (en) | Composition comprising the extracts of leaves of lindera obtusiloba for prevention and treatment of cardiovascular diseases | |
KR20150091771A (en) | Composition for treating or preventing diabetes contaning extract of caulerpa lentillifera | |
KR20100128668A (en) | An composition for preventing or improving diabete comprising an extract of rhus chinensis | |
KR20200084169A (en) | Composition for preventing or treating a hypertensive disease comprising extract of Indigofera pseudotinctoria Matsum or fraction thereof as active ingredient | |
KR20200118396A (en) | Composition for preventing and/or treating a hypertensive disease comprising an extract of Prunus mume Siebold et Zuccarini or a fraction thereof as an active ingredient | |
KR20110128068A (en) | Hopea odrata extact, pharmaceutical composition and healthy functional food |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880125072.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08870585 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008870585 Country of ref document: EP |